Sentence examples for replicating phase from inspiring English sources

The fragment analysis suggests that substructures like hetero_N_nonbasic, heterocyclic, carboxylic_ester, and hetero_N_basic_no_H are predominant in replicating phase inhibitors while hetero_O, ketone, secondary_mixed_amine are preferred in the non-replicative phase inhibitors.

This dataset involved screening of 2294 compounds from the BioAssay-488890 and identified 1453 inhibitors and 841 non-inhibitors for M.tb residing in replicating phase.

We observed that the mean value of molecular weight, Atom count and number of rotatable bonds (RBN) was significantly higher (p < 0.05) in inhibitors of replicating phase as compared to non-inhibitors whereas the lower mean value of these descriptors was observed in case of inhibitors of non-replicating phase as compared to non-inhibitors [Table 1].

Therefore, it appears that bacteriostatic effect of our antisense construct in actively replicating phase in the first 14 days was due to presence of higher ATP levels while sharp bactericidal activity seen at day 14 onwards following antisense downregulation of ppk may be related to low ATP levels during late stage of growth thus making mycobacteria more vulnerable in this phase.

Low GFs mediated this suppression by reducing the fraction of hepatocytes in the replicating phase of the cell cycle (Fig.  8b and c).

The Rpfs, secreted or membrane-anchored peptidoglycan/glycosyl hydrolases [ 204, 205] were originally identified in Micrococcus luteus, promoting the recovery of bacteria from latency to a replicating phase [ 206].

Although clopidogrel showed a significant association for several hundred genes in the discovery phase, these did not replicate in the replication phase.

Ten replicate Phase runs were conducted using 1000 burnin steps and 1000 iterations.

These were multinational, replicate, phase III, multicentre, randomised, double-blind, active-controlled, five-arm, parallel-group studies, registered with ClinicalTrials.gov (Study 1237.5: NCT01431274; Study 1237.6: NCT01431287) (fig. 1).

The safety of the combination has subsequently been assessed in a pooled safety analysis of two replicate phase III tiotropium + olodaterol FDC studies (Study 1237.5: NCT01431274; Study 1237.6: NCT01237.67).

In the two replicate phase III INPULSIS® studies [ 2], nintedanib was shown to slow disease progression in patients with IPF by reducing the annual rate of decline in forced vital capacity (FVC) [ 3].